Management of hypomagnesemia in cancer patients receiving chemotherapy

Journal of Supportive Oncology

Volumn 6, Issue 5, 2008, Pages 243-248

  Saif, Muhammad Wasif ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOSPORIN; DIURETIC AGENT; DOXORUBICIN; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GALLIUM NITRATE; GEFITINIB; GENTAMICIN; GLUCONATE MAGNESIUM; MAGNESIUM; MAGNESIUM DERIVATIVE; MAGNESIUM SULFATE; OXALIPLATIN; PANITUMUMAB; PENTAMIDINE; RECOMBINANT INTERLEUKIN 2; TACROLIMUS; UNINDEXED DRUG; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG RECHALLENGE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FLUSHING; HEART ARRHYTHMIA; HEAT SENSATION; HIGH RISK POPULATION; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; INTESTINE ABSORPTION; KIDNEY TUBULE DISORDER; LABORATORY TEST; MAGNESIUM BLOOD LEVEL; MAGNESIUM DEFICIENCY; MAGNESIUM DEPLETION; MAGNESIUM EXCRETION; MAGNESIUM METABOLISM; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; SIDE EFFECT; SOLID TUMOR; ST SEGMENT DEPRESSION; SWEATING;

ANTINEOPLASTIC AGENTS; CISPLATIN; CYCLOSPORINE; ENZYME INHIBITORS; HUMANS; MAGNESIUM DEFICIENCY; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 45249122468     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Schimatschek HF, Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res 2001;14:283-290. [11794636]
2. Ma J, Folsom AR, Melnick SL, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 1995;48:927-940. [7782801]
3. Wolf FI, Maier JA, Nasulewicz A, et al. Magnesium and neoplasia:from carcinogenesis to tumor growth and progression or treatment. Arch Biochem Biophys 2007;458:24-32. [16564020]
4. Rivlin RS. Magnesium deficiency and alcohol intake:mechanisms, clinical significance and possible relation to cancer development (a review).J Am Coll Nutr 1994;13:416-423. [7836619]
5. Mouw DR, Latessa RA, Hickner J. Clinical inquiries. What are the causes of hypomagnesemia? J Fam Pract 2005;54:174-176. [15689296]
6. Lajer H, Daugaard G.Cisplatin and hypomagnesemia. Cancer Treat Rev 1999;25:47-58. [10212589]
7. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979;90:929-931. [375794]
8. Martin M, Diaz-Rubio E, Casado A, LópezVega JM, Sastre J, Almenarez J.Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia: results of a controlled trial. Am J Clin Oncol 1992;15:348-351. [1514533]
9. Foster BJ, Clagett-Carr K, Leyland-Jones B, Hoth D. Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev 1985;12(suppl A):43-49. [3910221]
10. Nozue T, Kobayashi A, Kodama T, et al. Pathogenesis of cyclosporine-induced hypomagnesemia. J Pediatr 1992;120:638-640. [1552407]
11. Navaneethan SD, Sankarasubbaiyan S, Gross MD, Jeevanantham V, Monk RD. Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc 2006;38:1320-1322. [16797291]
12. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007;8:387-394. [17466895]
13. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-1224. [16106027]
14. Sobrero A, Fehrenbacher L, Rivera F, et al. Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial. Presented at the American Association for Cancer Research Annual Meeting; April 14-18, 2007; Los Angeles, Calif.
15. Van Cutsem E, Nowacki M, Lang I, et al: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC):the CRYSTAL trial. Presented at the American Association for Cancer Research Annual Meeting; April 14-18, 2007; Los Angeles, Calif.
16. Jonker DJ, Karapetis CS, Moore M, et al. Randomized phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Presented at the American Association for Cancer Research Annual Meeting; April 14-18, 2007; Los Angeles, Calif.
17. Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 2006;6:152-156. [16945172]
18. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary:panitumumab (Vectibix). Oncologist 2007;12:577-583. [17522246]
19. Saif MW, Cohenuram M.Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:118-124. [16945167]
20. Hecht J, Chidiac T, Mitchell E, et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC) (abstract 33). Proceedings of the 9th World Congress on Gastrointestinal Cancer in Barcelona, Spain, 2007.
21. Whang R, Ryder KW. Frequency of hypomagnesemia and hypermagnesemia: requested vs routine. JAMA 1990;263:3063-3064. [2342219]
22. Rubeiz GJ, Thill-Baharozian M, Hardie D, Carlson RW. Association of hypomagnesemia and mortality in acutely ill medical patients. Crit Care Med 1993;21:203-209. [8428470]
23. Iannello S, Belfiore F. Hypomagnesemia: a review of pathophysiological, clinical and therapeutical aspects. Panminerva Med 2001;43:177-209. [11579331]
24. Pearson ML. Guideline for the prevention of intravascular device-related infections - part II: recommendations for the prevention of nosocomial intravascular device-related infections. Am J Infect Control 1996;24:277-282. [8870911]